<h4>Objective</h4>Satralizumab, a monoclonal antibody targeting the interleukin-6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). This evidence concerns the gene IL6R and neuromyelitis optica.